Allarity Therapeutics initiates phase II trial of Ixempra in Europe for the treatment of metastatic breast cancer

Allarity Therapeutics A/S announced that it has enrolled the first patient in its European Phase II clinical trial of Ixempra (ixabepilone) for the treatment of metastatic breast cancer.

The FDA approved Ixempra, a microtubulin inhibitor, in 2007 for the treatment of metastatic breast cancer. Allarity holds exclusive European option rights to Ixempra from the pharmaceutical company R-Pharm U.S., LLC, which previously acquired global rights to the drug from Bristol-Myers Squibb (BMS). Allarity has previously developed and validated a Drug Response Predictor (DRP) companion diagnostic specific for the drug.